Professor David Nutt has spent a career making the argument for a rational, evidence-based approach to drug policy and drug use. The scientific evidence still challenges perceived wisdom on drugs and for that reason can appear to be contentious. In this podcast, the Professor explores the actual harms and potential benefits of various drugs, challenging myths surrounding classification and legislation, and exploring the societal impact of poorly informed drug policy. Using evidence in public policy should not be controversial. A podcast for anyone interested in understanding the scientific truth about drugs, free from political or moral concern.
https://drugscience.org.uk/
episode 77: 77. Is Depression Evolutionary? with Dr Charles Raison
Is depression evolutionary? Is inflammation good or bad? Can sleep be bad for you? Tune in to find out.
Depression is a complex and debilitating mental health disorder that affects millions of people worldwide. Despite the prevalence of depression, its causes and origins are still not entirely understood. In this episode of the Drug Science Podcast, we explore the evolutionary perspective on depression with renowned psychiatrist and researcher, Dr. Charles Raison.
Dr. Charles Raison is a psychiatrist and professor at the University of Wisconsin-Madison and Emory University. Having moved from the field of anthropology into psychiatry, Dr. Raison is now internationally recognized for his studies examining novel mechanisms involved in the development and treatment of major depression and other stress-related emotional and physical conditions, as well as for his work examining the physical and behavioral effects of compassion training.
The New Mind-Body Science of Depression
Andrew H. Miller
Interferon alpha
Paroxetine for the prevention of depression induced by high-dose interferon alfa
Infliximab
Tumor necrosis factor
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers
Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder
Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies
CRP
Interleukin 6 (IL-6)
Interleukin 1 beta
Wim Hof
Pivotal mental states
Usona Institute
COMPASS Pathways
Centre for Psychedelics and Spirituality
Psilocybin
MAPS
MDMA
Trial of Psilocybin versus Escitalopram for Depression
5-MeO-DMT
Sleeping with one eye open: loneliness and sleep quality in young adults